Neurologic DisorderNCT06542952
Statistical Analysis of Prevalence, Incidence, Comorbidities and Medical Expense in Epileptic Children in Taiwan Based on National Health Research Insurance Database.
An observational study of Neurologic Disorder and Seizure Disorder, run by National Taiwan University Hospital at 2 sites in Taiwan.
Trial summary
Epilepsy is a common disease in pediatric neurology. In recent years, due to the promotion of Taiwan's health insurance and the advancement of related medical treatments and anti-epileptic drugs, the prevalence, incidence, and related comorbidities of childhood epilepsy in Taiwan are expected, as well as the number of… Read more about this study
- Who is it for?
- Ages 0 to 19 years
- Conditions the study is for
- Neurologic Disorder, Seizure Disorder
- What is being tested?
- seizure
- How many people
- 169,026 participants
- Where
- 2 sitesTaiwan
- Study dates
- 9 Mar 2018to 19 Feb 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 0 to 19 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: Patients suffering from epilepsy
Who may be able to join
- Targets aged 0~19 (<=19) in the home country
- Diagnosis code includes ICD9: 345.XX, ACODE:A225 (including outpatient and inpatient)
- Between 2001 and 2013, those who had seen a doctor three times in a row with epilepsy diagnosis codes and used anti-epileptic drugs
Who cannot join
- Exclude those who sought medical treatment for epilepsy from 2001 to 2013, but the number of medical visits (outpatient + hospitalization) <3 times, and exclude those who did not take medication from 2001 to 2013.
Trial locations and contacts
2 sites in 1 country.
Taiwan2 sites
National Taiwan University Hospital
Tainan, 100
Department of Pediatrics, National Taiwan University Hospital
Taipei
About this study
Official title: Statistical Analysis of Prevalence, Incidence, Comorbidities and Medical Expense in Epileptic Children in Taiwan Based on National Health Research Insurance Database
Epilepsy is a common disease in pediatric neurology. In recent years, due to the promotion of Taiwan's health insurance and the advancement of related medical treatments and anti-epileptic drugs, the prevalence, incidence, and related comorbidities of childhood epilepsy in Taiwan are expected, as well as the number of epilepsy patients in different regions or different age groups. and medical costs may change. This study aims to collect data from the National Health Insurance Database through the National Institutes of Health, review relevant data on childhood epilepsy patients from 2001 to 2013, and analyze trends to discuss the impact of universal health insurance and medical progress on childhood epilepsy patients. Impact.
- Conditions
- Neurologic Disorder, Seizure Disorder
- Being tested
- seizure
- Medical subject headings
- Nervous System Diseases, Epilepsy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
seizureOther
epileptic children
What is being measured
The primary outcome is the main question the study is designed to answer.
Statistical Analysis of prevalence, incidence, comorbidities and medical expense medical expense in epileptic children in Taiwan based
in epileptic children in Taiwan based
Measured: 2001-2013
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Aug 2024
- Study start9 Mar 2018
- Primary completion4 Jan 2019
- Study completion19 Feb 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neurologic DisorderStudies of the same condition, open and under way.
- More trials run by National Taiwan University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 169,026 participants (actual)
Sponsor and investigators
- Lead sponsor
- National Taiwan University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, National Taiwan University Clinical Trial Center, National Taiwan University Hospital
- Investigators
- Mei Lan Liou, master, Study director, National Taiwan University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06542952
- Sponsor's protocol ID
- 201802028RINB
- Status last verified
- Aug 2024
- First submitted
- 5 Aug 2024
- Last updated
- 7 Aug 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Aug 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Statistical Analysis of Prevalence, Incidence, Comorbidities and Medical Expense in Epileptic Children in Taiwan Based on National Health Research Insurance Database
- ClinicalTrials.gov ID
- NCT06542952
- Acronym / sponsor ID
- 201802028RINB
- Conditions
- Neurologic Disorder, Seizure Disorder
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 169,026 participants (actual)
- Lead sponsor
- National Taiwan University HospitalUniversity, hospital or other
- Study start
- 9 Mar 2018 (actual)
- Primary completion
- 4 Jan 2019 (actual)
- Study completion
- 19 Feb 2021 (actual)
- First posted
- 7 Aug 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Epilepsy is a common disease in pediatric neurology. In recent years, due to the promotion of Taiwan's health insurance and the advancement of related medical treatments and anti-epileptic drugs, the prevalence, incidence, and related comorbidities of childhood epilepsy in Taiwan are expected, as well as the number of epilepsy patients in different regions or different age groups. and medical costs may change. This study aims to collect data from the National Health Insurance Database through the National Institutes of Health, review relevant data on childhood epilepsy patients from 2001 to 2013, and analyze trends to discuss the impact of universal health insurance and medical progress on childhood epilepsy patients. Impact.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Ages
- 0 to 19 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- Patients suffering from epilepsy
Key inclusion criteria (3 listed)
- Targets aged 0~19 (<=19) in the home country
- Diagnosis code includes ICD9: 345.XX, ACODE:A225 (including outpatient and inpatient)
- Between 2001 and 2013, those who had seen a doctor three times in a row with epilepsy diagnosis codes and used anti-epileptic drugs
Key exclusion criteria (1 listed)
- Exclude those who sought medical treatment for epilepsy from 2001 to 2013, but the number of medical visits (outpatient + hospitalization) <3 times, and exclude those who did not take medication from 2001 to 2013.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| seizureepileptic children | Other | – |
Primary outcome
Statistical Analysis of prevalence, incidence, comorbidities and medical expense medical expense in epileptic children in Taiwan based
Time frame: 2001-2013
in epileptic children in Taiwan based
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Aug 2024.
Related trials for Neurologic Disorder
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Not yet recruiting
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Aphasia (BG-Aphasia-01)
Expressive Aphasia, Aphasia Following Cerebral Infarction
Not yet recruiting
Feasibility of a Robot-Guided Active Play Intervention for Children With Cerebral Palsy
Cerebral Palsy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mei Lan Liou, master study director
National Taiwan University Hospital
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Neurologic Disorder and Seizure Disorder, run by National Taiwan University Hospital at 2 sites in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Statistical Analysis of prevalence, incidence, comorbidities and medical expense medical expense in epileptic children in Taiwan based (time frame: 2001-2013). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Aug 2024.